Secondary Stock OfferingsBy The Online Investor Staff, updated Sat., May. 8, 6:02 AM
|This Slide: #17 of 25|
Slide #17. Evolus, Inc. — Secondary Offering
Evolus, Inc. (NASDAQ:EOLS)
Date of Pricing:
Price Per Share:
Secondary Offering Details:
Evolus, Inc. (Nasdaq: EOLS) announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. Evolus expects to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares in the offering are to be sold by Evolus. -updated 4/21- Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its public offering of 9,000,000 shares of its common stock at a public offering price of $9.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering to Evolus are expected to be $85.5 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Evolus has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about April 26, 2021, subject to satisfaction of customary closing conditions. All the shares in the offering are being sold by Evolus.
Evolus is a performance beauty company focused on delivering breakthrough products in the self-pay aesthetic market. Co.'s product, Jeuveau (prabotulinumtoxinA-xvfs), is a 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Co.'s primary market is the self-pay aesthetic market, which includes medical products purchased by physicians that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance.
EOLS SEC Filing Email Alerts Service
Open the EOLS Page at The Online Investor »
Buy (3.33 out of 4)